Marinus Pharmaceuticals (NASDAQ:MRNS) Given Neutral Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note published on Thursday morning,Benzinga reports. The firm currently has a $2.00 target price on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on the company. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a research report on Monday, September 23rd. Truist Financial lowered Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. StockNews.com started coverage on Marinus Pharmaceuticals in a research report on Sunday, November 10th. They issued a “hold” rating for the company. Finally, EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Nine equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Marinus Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ MRNS traded down $0.01 during trading hours on Thursday, reaching $0.30. 1,600,465 shares of the stock were exchanged, compared to its average volume of 1,584,877. The stock’s fifty day simple moving average is $1.24 and its 200 day simple moving average is $1.32. Marinus Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $11.26. The firm has a market capitalization of $16.71 million, a price-to-earnings ratio of -0.12 and a beta of 1.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.02. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 446.48%. The company had revenue of $8.54 million for the quarter, compared to the consensus estimate of $8.95 million. Research analysts predict that Marinus Pharmaceuticals will post -1.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. increased its holdings in shares of Marinus Pharmaceuticals by 39.5% in the third quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 117,255 shares during the period. Suvretta Capital Management LLC increased its holdings in shares of Marinus Pharmaceuticals by 32.8% in the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after purchasing an additional 1,253,901 shares during the period. GSA Capital Partners LLP increased its holdings in shares of Marinus Pharmaceuticals by 409.4% in the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after purchasing an additional 817,050 shares during the period. abrdn plc increased its holdings in shares of Marinus Pharmaceuticals by 146.1% in the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after purchasing an additional 1,578,329 shares during the period. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Marinus Pharmaceuticals by 70.3% in the third quarter. Assenagon Asset Management S.A. now owns 444,185 shares of the biopharmaceutical company’s stock worth $782,000 after purchasing an additional 183,396 shares during the period. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.